- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT03390504
Исследование эрдафитиниба по сравнению с винфлунином, доцетакселом или пембролизумабом у участников с прогрессирующим уротелиальным раком и отдельными аберрациями гена рецептора фактора роста фибробластов (FGFR) (THOR)
Исследование фазы 3 эрдафитиниба по сравнению с винфлунином, доцетакселом или пембролизумабом у субъектов с прогрессирующим уротелиальным раком и отдельными аберрациями гена FGFR
The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer harboring selected fibroblast growth factor receptor (FGFR) aberrations who have progressed after 1 or 2 prior treatments, at least 1 of which includes an anti-programmed death ligand 1(PD-[L]1) agent (cohort 1) or 1 prior treatment not containing an anti-PD-(L) 1 agent (cohort 2).
Обзор исследования
Статус
Условия
Подробное описание
A study of erdafitinib versus standard of care, consisting of chemotherapy (docetaxel or vinflunine) or anti-PD-(L) 1 agent pembrolizumab, in participants with advanced urothelial cancer and selected FGFR aberrations who have progressed on or after 1 or 2 prior treatments, at least 1 of which includes an anti-PD-(L) 1 agent (cohort 1) or 1 prior treatment not containing an anti-PD-(L) 1 agent (cohort 2). It will consist of screening, treatment phase (from randomization until disease progression, intolerable toxicity, withdrawal of consent or decision by investigator to discontinue treatment, post-treatment follow-up (from end-of-treatment to participants death, withdraws consent, lost to follow-up study completion for the respective cohort, whichever comes first). The study will have long term extension (LTE) period after clinical cutoff date is achieved for final analysis of each cohort and participants eligible in the opinion of the investigator, will continue to benefit from the study intervention. Efficacy, pharmacokinetics, biomarkers, patient reported outcomes, medical resource utilization and safety will be assessed.
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 3
Расширенный доступ
Контакты и местонахождение
Места учебы
-
-
-
Camperdown, Австралия, 2050
- Chris O'Brien Lifehouse
-
Frankston, Австралия, 3199
- Peninsula & South Eastern Haematology and Oncology Group
-
Kogarah, Австралия, 2217
- St George Hospital
-
Melbourne, Австралия, 3000
- Peter MacCallum Cancer Centre
-
Melbourne, Австралия, 3199
- Frankston Hospital
-
Murdoch, Австралия, 6150
- Fiona Stanley Hospital
-
-
-
-
-
Graz, Австрия, 8036
- LKH-Univ. Klinikum Graz
-
Linz, Австрия, 4020
- Ordensklinikum Linz GmbH Elisabethinen
-
Salzburg, Австрия, 5020
- LKH - Universitätsklinikum der PMU Salzburg
-
Vienna, Австрия, 1020
- Krankenhaus der Barmherzigen Brüder
-
Vienna, Австрия, A-1090
- Medical University Vienna MUV
-
-
-
-
-
Buenos Aires, Аргентина, C1426AGE
- Centro Oncológico Korben
-
Buenos Aires, Аргентина, C1419AHN
- Sociedade Beneficente de Senhoras Hospital Sirio Libanes
-
Buenos Aires, Аргентина, C1431FWN
- CEMIC Saavedra
-
Córdoba, Аргентина, X5000KPH
- Centro Urologico Profesor Bengio
-
Córdoba, Аргентина, C5000
- Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica
-
Mar del Plata, Аргентина, B7602CBM
- Hospital Privado de Comunidad
-
Pergamino, Аргентина, B2700CPM
- Centro de Investigacion Pergamino SA
-
Viedma, Аргентина, R8500ACE
- Clínica Viedma
-
-
-
-
-
Aalst, Бельгия, 9300
- OLV Ziekenhuis Aalst
-
Antwerp, Бельгия, 2020
- ZNA Middelheim
-
Brussels, Бельгия, 1200
- Cliniques Universitaires Saint Luc
-
Charleroi, Бельгия, 6000
- Clinique Notre Dame de Grâce
-
Ghent, Бельгия, 9000
- AZ Maria Middelares
-
Ghent, Бельгия, 9000
- UZ Gent
-
Liège, Бельгия, 4000
- CHC MontLegia
-
Wilrijk, Бельгия, 2610
- Sint-Augustinus AZ
-
Yvoir, Бельгия, 5530
- CHU UCL Namur - Site Godinne
-
-
-
-
-
Pleven, Болгария, 5800
- UMHAT 'Dr. Georgi Stranski', EAD
-
Plovdiv, Болгария, 4004
- Complex Oncology Center - Plovdiv EOOD
-
Sofia, Болгария, 1407
- Multiprofile Hospital for Active Treatment 'Tokuda Hospital Sofia'
-
Sofia, Болгария, 1797
- UMHAT Sofia Med
-
Varna, Болгария, 9010
- Multiprofile Hospital for Active Treatment 'Sveta Marina' EAD
-
-
-
-
-
Barretos, Бразилия, 14784-400
- Fundacao Pio XII
-
Belo Horizonte, Бразилия, 30130-100
- Universidade Federal De Minas Gerais - Hospital das Clínicas
-
Belo Horizonte, Бразилия, 30380-472
- Nucleo de Ensino e Pesquisa do Instituto Mario Penna
-
Curitiba, Бразилия, 80530-010
- Instituto de Oncologia do Parana
-
Curitiba, Бразилия, 81520 060
- Liga Paranaense de Combate ao Cancer
-
Goiânia, Бразилия, 74605-070
- Associacao de Combate ao Cancer em Goias - Hospital de Cancer Araujo Jorge
-
Itajaí, Бразилия, 88301-220
- Clínica de Neoplasias Litoral Ltda.
-
Jaú, Бразилия, 17210 080
- Fundacao Doutor Amaral Carvalho
-
Natal, Бразилия, 59075-740
- Liga Norte Riograndense Contra O Cancer
-
Porto Alegre, Бразилия, 90035-903
- Hospital das Clinicas de Porto Alegre
-
Porto Alegre, Бразилия, 91350 200
- Hospital Nossa Senhora da Conceicao S A
-
Rio de Janeiro, Бразилия, 22250 905
- Oncoclinicas Rio de Janeiro S A
-
Rio de Janeiro, Бразилия, 20231 050
- Ministerio da Saude Instituto Nacional do Cancer
-
Salvador, Бразилия, 41253-190
- Hospital Sao Rafael
-
Santo André, Бразилия, 09060-650
- CEPHO Centro de Estudos e Pesquisa de Hematologia e Oncologia
-
Sorocaba, Бразилия, 18030-005
- Instituto de Oncologia de Sorocaba Onco Clinicas Especializadas
-
São José do Rio Preto, Бразилия, 15090-000
- Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto Hospital de Base
-
São Paulo, Бразилия, 04502-001
- Instituto D Or de Pesquisa e Ensino IDOR
-
São Paulo, Бразилия, 01509 900
- Fundacao Antonio Prudente A C Camargo Cancer Center
-
São Paulo, Бразилия, 05652 900
- Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
-
São Paulo, Бразилия, 03102-002
- Instituto Brasileiro de Controle do Cancer - Sao Camilo Oncologia
-
São Paulo, Бразилия, 01308 050
- Sociedade Beneficente de Senhoras Hospital Sirio Libanes 1
-
-
-
-
-
Budapest, Венгрия, 1082
- Semmelweis Egyetem
-
Budapest, Венгрия, 1122
- Országos Onkológiai Intézet, Urogenitális Tumorok és Klinikai Farmakológiai Osztály
-
Budapest, Венгрия, H-1145
- Budapesti Uzsoki Utcai Korhaz
-
Nyíregyháza, Венгрия, 04400
- Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz
-
Pécs, Венгрия, 7624
- Pecsi Tudomanyegyetem Klinikai Kozpont
-
-
-
-
-
Berlin, Германия, 10967
- Vivantes Klinikum Am Urban
-
Braunschweig, Германия, 38126
- Stadtisches Klinikum Braunschweig gGmbH-Klinik fur Urologie und Uroonkologie
-
Dresden, Германия, 01307
- Universitatsklinikum Carl Gustav Carcus Dresden
-
Düsseldorf, Германия, 40225
- Universitaetsklinikum Duesseldorf
-
Erlangen, Германия, 91054
- Friedrich-Alexander Universitaet Urologische Universitaetskl
-
Frankfurt, Германия, 60590
- Universitatsklinikum Frankfurt
-
Freiburg im Breisgau, Германия, 79106
- Universitatsklinikum Freiburg
-
Greifswald, Германия, 17475
- Universitätsmedizin Greifswald
-
Göttingen, Германия, 37099
- Universitatsmedizin Gottingen
-
Hamburg, Германия, 22763
- Asklepios Klinik Altona
-
Hanover, Германия, 30625
- Medizinische Hochschule Hannover
-
Lübeck, Германия, 23538
- Universitatsklinikum Schleswig Holstein Campus Lubeck
-
Mannheim, Германия, 68167
- Medizinische Fakultät Mannheim der Universität Heidelberg
-
Münster, Германия, 48149
- Universitaetsklinikum Muenster
-
Nürtingen, Германия, 72622
- Studienpraxis Urologie Drs. Feyerabend
-
Regensburg, Германия, 93053
- Caritas-Krankenhaus St. Josef
-
Rostock, Германия, 18057
- Universitaetsmedizin Rostock
-
Velbert, Германия, 42551
- MVZ-Onkologie Velbert GbR
-
Weiden, Германия, 92637
- Kliniken Nordoberpfalz AG/Klinikum Weiden
-
-
-
-
-
Athens, Греция, 15125
- Athens Medical Center
-
Athens, Греция, 11526
- Errikos Dunant Hospital Center
-
Athens, Греция, 15562
- Metropolitan General A E
-
Athens, Греция, 115 28
- University of Athens Medical School - Regional General Hospi
-
Larissa, Греция, 41110
- University Hospital Of Larissa
-
Pátrai, Греция, 26504
- University General Hospital of Rio Patras
-
Thessaloniki, Греция, 54645
- Euromedica General Clinic
-
Thessaloniki, Греция, 14564
- Interbalkan European Medical Center
-
Thessaloniki, Греция, 56403
- Papageorgiou General Hospital Of Thessaloniki
-
-
-
-
-
Haifa, Израиль, 31096
- Rambam Health Care Campus
-
Jerusalem, Израиль, 91120
- Hadassah Medical Center
-
Kfar Saba, Израиль, 44281
- Meir Medical Center
-
Petach Tikvah, Израиль, 49100
- Rabin Medical Center, Beilinson Hospital
-
Tel Aviv, Израиль, 64239
- Sourasky Medical Center
-
Tel HaShomer, Израиль, 52621
- The Chaim Sheba Medical Center
-
Tzrifin, Израиль, 70300
- Assaf Harofeh Medical Center
-
-
-
-
-
Badajoz, Испания, 06006
- Hosp. Univ. Infanta Cristina
-
Badalona, Испания, 08916
- Institut Català D'Oncologia-Hospital Universitari Germans Trias I Pujol
-
Barcelona, Испания, 08041
- Hosp. de La Santa Creu I Sant Pau
-
Barcelona, Испания, 08036
- Hosp Clinic de Barcelona
-
Cáceres, Испания, 10003
- Hosp. San Pedro de Alcantara
-
Córdoba, Испания, 14004
- Hosp Reina Sofia
-
Granada, Испания, 18014
- Hosp. Univ. Virgen de Las Nieves
-
Jaén, Испания, 23007
- Complejo Hospitalario de Jaen
-
Las Palmas de Gran Canaria, Испания, 35016
- Hosp. Univ. Insular de Gran Canaria
-
Lugo, Испания, 27003
- Hosp. Univ. Lucus Augusti
-
Madrid, Испания, 28041
- Hosp. Univ. 12 de Octubre
-
Madrid, Испания, 28046
- Hosp. Univ. La Paz
-
Majadahonda, Испания, 28220
- Hosp. Univ. Pta. de Hierro Majadahonda
-
Manresa, Испания, 08243
- ALTHAIA, Xarxa Assistencial Universitària de Manresa
-
Pamplona, Испания, 31008
- Hosp. de Navarra
-
Seville, Испания, 41013
- Hosp. Virgen Del Rocio
-
Seville, Испания, 41009
- Hosp. Virgen Macarena
-
Valencia, Испания, 46014
- Hosp. Gral. Univ. Valencia
-
Valencia, Испания, 46026
- Hosp. Univ. I Politecni La Fe
-
Zaragoza, Испания, 50009
- Hosp. Univ. Miguel Servet
-
-
-
-
-
Alessandria, Италия, 15121
- Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo Alessandria
-
Arezzo, Италия, 52100
- Ospedale S. Donato - Asl 8 Arezzo
-
Aviano, Италия, 33081
- CRO IRCCS Istituto Nazionale Tumori
-
Bergamo, Италия, 24127
- Azienda Ospedaliera Papa Giovanni XXIII
-
Brescia, Италия, 25123
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia Presidio Spedali Civili
-
Cremona, Италия, 26100
- Istituti Ospitalieri di Cremona, AO di Cremona
-
Florence, Италия, 50139
- Oncologia Medica
-
Genova, Италия
- SPDC Villa Scassi
-
Meldola, Италия, 47014
- IRST Meldola Forli
-
Milan, Италия, 20132
- IRCCS Ospedale San Raffaele
-
Milan, Италия, 20133
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
Milan, Италия, 20141
- European Institute of Oncology
-
Modena, Италия, 41124
- AOU Policlinico di Modena
-
Naples, Италия, 80131
- IRCCS-Fondazione Pascale
-
Novara, Италия, 28100
- Ospedale Maggiore della Carita
-
Orbassano, Италия, 10043
- Aou San Luigi Gonzaga
-
Padova, Италия, 35128
- Istituto Oncologico Veneto Iov Irccs Padova
-
Parma, Италия, 43126
- AOU di Parma
-
Pavia, Италия, 27100
- IRCCS Policlinico San Matteo
-
Pavia, Италия, 27100
- Ist. Clinici Scientifici Maugeri - Unità Operativa di Oncolo
-
Pisa, Италия, 56126
- Azienda Ospedaliero Universitaria Pisana
-
Poggibonsi (SI), Италия, 53100
- Usl 7 Siena - Ospedale Alta Valdelsa ASL TOSCANA SUD-EST
-
Province of Macerata, Италия, 62100
- UOC Oncologia Ospedale Provinciale di Macerata
-
Roma, Италия, 00168
- Fondazione Policlinico Universitario A Gemelli IRCCS
-
Siena, Италия, 53100
- Azienda Ospedaliera Universitaria Senese Policlinico Santa Maria alle Scotte
-
Torino, Италия, 10123
- Oncologia Medica-Città Della Salute E Della Scienza Di Torino
-
Torrette Di Ancona, Италия, 60126
- Azienda Ospedaliero - Universitaria Ospedali Riuniti
-
-
-
-
British Columbia
-
Kelowna, British Columbia, Канада, V1Y 5L3
- BC Cancer Agency - Southern Interior
-
Vancouver, British Columbia, Канада, V5Z 4E6
- Vancouver Cancer Centre
-
-
Manitoba
-
Winnipeg, Manitoba, Канада, R3E 0V9
- Cancercare Manitoba
-
-
Ontario
-
Thunder Bay, Ontario, Канада, P7B 6V4
- Thunder Bay Regional Health Sciences Centre
-
Toronto, Ontario, Канада, M5G 2M9
- Princess Margaret Hospital- UHN
-
-
Saskatchewan
-
Regina, Saskatchewan, Канада, S4T 7T1
- Saskatchewan Cancer Agency (SCA) - Allan Blair Cancer Centre
-
-
-
-
-
Beijing, Китай, 100730
- Beijing Hospital
-
Beijing, Китай, 100730
- Peking Union Medical College Hospital
-
Beijing, Китай, 100191
- Peking University Third Hospital
-
Beijing, Китай, 100050
- Beijing Friendship Hospital
-
Beijing, Китай, 100034
- Peking University First Hospital
-
Beijing, Китай, 100021
- Cancer Hospital Chinese Academy of Medical Sciences
-
Changchun, Китай, 130021
- The First Bethune Hospital of Jilin University
-
Chengdu, Китай, 610041
- Sichuan University Huaxi Hospital
-
Chengdu, Китай, 610000
- Sichuan Provincial Peoples Hospital
-
Chongqing, Китай, 400030
- Chongqing University Cancer Hospital
-
Guangzhou, Китай, 510180
- Guangzhou First Municipal People's Hospital
-
Guangzhou, Китай, 510120
- Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
-
Guangzhou, Китай, 510060
- Sun Yat Sen University Cancer Center
-
Hangzhou, Китай, 310014
- Zhejiang Provincial People's Hospital
-
Hangzhou, Китай, 310020
- Sir Run Run Shaw Hospital Zhejiang University School of Medicine
-
Nanchang, Китай, 330006
- The First Affliated Hospital Of Nanchang University
-
Nanjing, Китай, 210009
- Jiangsu Cancer Hospital
-
Nanjing, Китай, 210008
- Nanjing Drum Tower Hospital
-
Shanghai, Китай, 200127
- Renji Hospital, Shanghai Jiaotong University School of Medicine
-
Shanghai, Китай, 200400
- Huadong Hospital Affiliated to Fudan University
-
Shenyang, Китай, 110004
- Shengjing Hospital Of China Medical University
-
Shenzhen, Китай, 518055
- Shenzhen university General Hospital
-
Wenzhou, Китай, 325000
- First Affiliated Hospital Of Wenzhou Medical College
-
Xi'an, Китай, 710061
- The First Affiliated Hospital of Xian Jiaotong University
-
-
-
-
-
Aguascalientes, Мексика, 20230
- Medicos Especialistas en Cancer, S.C.
-
Chihuahua City, Мексика, 31000
- Centro Estatal de Cancerología de Chihuahua
-
Naucalpan, Мексика, 53100
- Oncologia Integral Satelite
-
-
-
-
-
Amsterdam, Нидерланды, 1066 CX
- Antoni van Leeuwenhoek
-
Nieuwegein, Нидерланды, 3430 EM
- St. Antonius Ziekenhuis Nieuwegein
-
The Hague, Нидерланды, 2545 CH
- Haga ziekenhuis
-
-
-
-
-
Bydgoszcz, Польша, 85 796
- Centrum Onkologii im Prof F Lukaszczyka w Bydgoszczy
-
Warsaw, Польша, 02-507
- Centralny Szpital Kliniczny MSWiA w Warszawie
-
Warsaw, Польша, 02-781
- Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
-
Wroclaw, Польша, 50 556
- Uniwersytecki Szpital Kliniczny we Wroclawiu
-
-
-
-
-
Lisbon, Португалия, 1400-038
- Champalimaud Foundation Champalimaud Centre
-
Lisbon, Португалия, G1R 2J6
- Uls Sao Jose - Hosp. Sto Antonio Dos Capuchos
-
Lisbon, Португалия, 1500-458
- Hospital Lusíadas
-
Lisbon, Португалия, 1649-035
- H. Santa Maria - Centro Hospitalar de Lisboa Norte
-
Porto, Португалия, 4200072
- Instituto Portugues de Oncologia
-
-
-
-
-
Barnaul, Россия, 656049
- Altai Regional Oncology Dispensary
-
Chelyabinsk, Россия, 454087
- Chelyabinsk Regional Clinical Center Of Oncology And Nuclear Medicine
-
Irkutsk, Россия, 664035
- Irkutsk Regional Oncology Dispensary
-
Ivanovo, Россия, 153040
- Ivanovo Regional Oncology Dispensary
-
Kostroma, Россия, 156005
- Kostroma regional oncology dispensary
-
Kuzmolovsky, Россия, 188663
- Leningrad Regional Oncology Dispensary
-
Moscow, Россия, 105077
- City Clinical Hospital n.a. D.D.Pletnev
-
Moscow, Россия, 117997
- Russian Scientific Center of Roentgenoradiology
-
Moscow, Россия, 119991
- I.M. Sechenov First Moscow State Medical University
-
Moscow, Россия, 125284
- Hertzen Oncology Research Institute
-
Moscow, Россия, 115478
- FSBSI 'N. N. Blokhin Russian Cancer Research Center'
-
Nal'chik, Россия, 360017
- City Clinical Hospital #1
-
Nizhny Novgorod, Россия, 603109
- Privolzhsky District Medical Center under the Federal Medico-Biological Agency
-
Omsk, Россия, 644013
- Clinical Oncology Dispensary
-
Pyatigorsk, Россия, 357502
- GBUZ of Stavropol region Pyatigorsk Oncological Dispensary
-
Saint Petersburg, Россия, 196603
- Private Medical Institution Euromedservice
-
Saint Petersburg, Россия, 197758
- Russian Scientific Center of Radiology and Surgical Technologies
-
Saint Petersburg, Россия, 192148
- LLC 'Strategic Medical Systems'
-
Saint Petersburg, Россия, 195067
- Clinical hopital n/a Petra velikogo
-
Saint Petersburg, Россия, 197022
- Pavlov First Saint Petersburg State Medical University
-
Saint Petersburg, Россия, 197758
- Saint-Petersburg Clinical Scientific And Practical Center For Special Types Of Medical Care
-
Saransk, Россия, 430032
- FGBOU Vo Mordovian National Research State University N. A. N.P. Ogareva
-
Saratov, Россия, 410000
- Saratov State Medical University
-
Smolensk, Россия, 214031
- LLC Uromed
-
Sochi, Россия, 354057
- GBUZ Oncology Centre #2 of Healthcare Department of Krasno
-
Tyumen, Россия, 625041
- Multifunctional clinical medical center 'Medical city'
-
Ufa, Россия, 450000
- Bashkiria State Medical University
-
Vologda, Россия, 160012
- Vologda Regional Oncological Dispensary
-
-
-
-
-
Bristol, Соединенное Королевство, BS2 8ED
- University Hospitals Bristol - Bristol Haematology & Oncolog
-
London, Соединенное Королевство, W1G 6AD
- Sarah Cannon Research Institute
-
London, Соединенное Королевство, W6 8RF
- Charing Cross Hospital
-
London, Соединенное Королевство, EC1A 7BE
- St Bartholomew's Hospital
-
Manchester, Соединенное Королевство, M20 4BX
- The Christie NHS Foundation Trust Christie Hospital
-
Plymouth, Соединенное Королевство, PL6 8QH
- Derriford Hospital-Department of Medical Oncology
-
Sheffield, Соединенное Королевство, S10 2 RX
- University of Sheffield
-
Southampton, Соединенное Королевство, SO16 6YD
- Southampton General Hospital
-
Sutton, Соединенное Королевство, SM2 5NG
- Royal Marsden Hospital
-
-
-
-
Alaska
-
Anchorage, Alaska, Соединенные Штаты, 99503
- Alaska Urological Institute dba Alaska Clinical Research Center
-
-
California
-
Sacramento, California, Соединенные Штаты, 95817
- University of Calif Davis Medical Center
-
St. Helena, California, Соединенные Штаты, 94574
- St. Helena Hospital - Martin-O'Neil Cancer Center
-
-
District of Columbia
-
Washington D.C., District of Columbia, Соединенные Штаты, 20007
- MedStar Georgetown University Hospital
-
-
Florida
-
Miami, Florida, Соединенные Штаты, 33136
- University of Miami Sylvester Cancer Center
-
Orange, Florida, Соединенные Штаты, 32763
- Mid Florida Hematology Oncology
-
-
Georgia
-
Atlanta, Georgia, Соединенные Штаты, 30318-0922
- Piedmont Cancer Institute
-
-
Illinois
-
Chicago, Illinois, Соединенные Штаты, 60612
- Rush University
-
Hines, Illinois, Соединенные Штаты, 60141
- Edward Hines Jr V A Hospital
-
-
Kentucky
-
Louisville, Kentucky, Соединенные Штаты, 40207
- Norton Cancer Institute
-
-
Maryland
-
Lanham, Maryland, Соединенные Штаты, 20706
- Maryland Oncology Hematology, PA
-
-
Michigan
-
Ann Arbor, Michigan, Соединенные Штаты, 48109-5000
- University of Michigan Health System
-
-
Nevada
-
Reno, Nevada, Соединенные Штаты, 89509
- VA Sierra Nevada Health Care System
-
-
New Hampshire
-
Lebanon, New Hampshire, Соединенные Штаты, 03756
- Dartmouth Hitchcock Medical Center
-
-
New York
-
New York, New York, Соединенные Штаты, 10029
- Weill Cornell Medical College
-
The Bronx, New York, Соединенные Штаты, 10461
- Montefiore Medical Center
-
-
North Carolina
-
Charlotte, North Carolina, Соединенные Штаты, 28204
- Levine Cancer Institute, Carolinas HealthCare System
-
Salisbury, North Carolina, Соединенные Штаты, 28144
- W G Bill Hefner VA Medical Center
-
-
Ohio
-
Cincinnati, Ohio, Соединенные Штаты, 45242
- Oncology Hematology Care
-
-
Texas
-
Fort Worth, Texas, Соединенные Штаты, 76104
- The Center for Cancer and Blood Disorders
-
Houston, Texas, Соединенные Штаты, 77030
- MD Anderson Cancer Center
-
Houston, Texas, Соединенные Штаты, 77024
- Texas Oncology-Memorial City
-
Tyler, Texas, Соединенные Штаты, 75702
- Texas Oncology Tyler
-
-
Virginia
-
Fairfax, Virginia, Соединенные Штаты, 22031
- INOVA Dwiight &Martha Schar Cancer Institute
-
Norfolk, Virginia, Соединенные Штаты, 23502
- Virginia Oncology Associates
-
-
Washington
-
Seattle, Washington, Соединенные Штаты, 98108
- VA Puget Sound Healthcare System
-
-
-
-
-
Kaohsiung City, Тайвань, 807
- Kaohsiung Medical University Chung Ho Memorial Hospital
-
Niao-Sung Hsiang, Тайвань, 833
- Chang Gung Medical Foundation
-
Taichung, Тайвань, 40447
- China Medical University Hospital
-
Taichung, Тайвань, 40705
- Taichung Veterans General Hospital
-
Tainan, Тайвань, 70403
- National Cheng Kung University Hospital
-
Tainan, Тайвань, 710
- Chi Mei Medical Center Yong Kang
-
Taipei, Тайвань, 10002
- National Taiwan University Hospital
-
Taipei, Тайвань, 11217
- Taipei Veterans General Hospital
-
Taipei, Тайвань, 10449
- Mackay Memorial Hospital
-
Taipei, Тайвань, 11259
- Koo Foundation Sun Yat-Sen Cancer Center
-
Taoyuan, Тайвань, 333
- Chang-Gung Memorial Hospital, LinKou Branch
-
-
-
-
-
Adana, Турция (Туркие), 01120
- Baskent University Adana Practice and Research Center Kisla Health Campus
-
Ankara, Турция (Туркие), 6100
- Hacettepe University Medical Faculty
-
Istanbul, Турция (Туркие), 34098
- Istanbul Universitesi Cerrahpasa Tip Fakultesi
-
Istanbul, Турция (Туркие), 34147
- Bakirkoy Training and Research Hospital
-
Istanbul, Турция (Туркие), 34722
- T C Saglik Bakanlıgi Goztepe Prof Dr Suleyman Yalcın Sehir Hastanesi
-
Istanbul, Турция (Туркие), 34214
- Medipol Mega University Hospital
-
Istanbul, Турция (Туркие), 34093
- Bezmialem University Medical Faculty
-
Istanbul, Турция (Туркие), 34890
- Pendik Training and Research Hospital
-
Izmir, Турция (Туркие), 35340
- Dokuz Eylul Universitesi Tip Fakultesi
-
Izmir, Турция (Туркие), 35100
- Ege University
-
Kocaeli, Турция (Туркие)
- Kocaeli University Medical Faculty
-
Malatya, Турция (Туркие), 44400
- Inonu Universitesi Turgut Ozal Tip Merkezi, Ic Hastaliklari
-
-
-
-
-
Dnipro, Украина, 49102
- Dnipropetrovsk State Medical Academy, Dnipropetrovsk City Multifield Clinical Hospital # 4
-
Dnipro, Украина, 49100
- Municipal Institution 'Clinical Oncology Dispensary' Under Dnipropetrovsk Regional Council
-
Dnipropetrovsk, Украина, 49005
- MI Dnipropetrovsk Region Clinical Hospital n a I.I.Mechnikov
-
Ivano-Frankivsk, Украина, 76008
- Ivano-Frankivsk Regional Clinical Hospital
-
Kharkiv, Украина, 61070
- Municipal non-profit enterprise 'Regional Center of Oncology'
-
Kharkiv, Украина, 61037
- Regional Medical Clinical Center for Urology and Nephrology named after V.I. Shapoval
-
Kyiv, Украина, 03022
- National Cancer Institute
-
Kyiv, Украина, 03115
- State Institution Institute of Urology NAMS of Ukraine based on Kyiv City Clinical Oncology Center
-
Lviv, Украина, 79010
- Communal Noncommercial Enterprise of Lviv Regional Council 'Lviv Regional Clinical Hospital'
-
Uzhhorod, Украина, 88000
- Transkarpathian Regional University Oncology Clinic
-
Vinnitsa, Украина, 21029
- Podilskiy Regional Center of Oncology
-
Zaporizhzhya, Украина, 69040
- Zaokod
-
Zaporizhzhya, Украина, 69600
- Zaporizhzhia medical Academy of postgraduate education, Zaporizhzhia Regoinal Clinical Hospital
-
-
-
-
-
Angers, Франция, 49055
- Institut de Cancerologie de l Ouest ICO
-
Besançon, Франция, 25030
- Hopital Jean Minjoz
-
Bordeaux, Франция, 33000
- Institut Bergonie
-
Brest, Франция, 29609
- CHRU Brest - Hopital Morvan
-
Clermont-Ferrand, Франция, 63011
- Centre Jean Perrin
-
Dijon, Франция, 21079
- Centre Georges-François Leclerc
-
Lille, Франция, 59000
- Centre Oscar Lambret
-
Lille, Франция, 59000
- Hôpital Privé Le Bois
-
Lorient, Франция, 56322
- Groupe Hospitalier Bretagne Sud
-
Marseille, Франция, 13005
- Hopital de la Timone
-
Montpellier, Франция, 34298
- Institut Regional du Cancer de Montpellier Val d'Aurelle
-
Nice, Франция, 06189
- Centre Antoine Lacassagne
-
Nîmes, Франция, 30029
- Institut de Cancérologie du Gard
-
Paris, Франция, 75475
- Hospital Saint-Louis
-
Paris, Франция, 75015
- Hopital Europeen Georges-Pompidou
-
Pierre-Bénite, Франция, 69495
- Hospices Civils de Lyon HCL
-
Poitiers, Франция, 86021
- CHU De Poitiers
-
Rennes, Франция, 35062
- Centre Eugene Marquis
-
Ris-Orangis, Франция, 91130
- Centre de radiothérapie et d'Oncologie médicale de l'Essonne
-
Saint-Priest-en-Jarez, Франция, 42271
- Institut de Cancérologie de Loire
-
Strasbourg, Франция, 67098
- Hôpitaux Universitaires de Strasbourg - Hôpital de Hautepierre
-
Toulouse, Франция, 31059
- Institut Claudius Regaud
-
Valenciennes, Франция, 59300
- Centre Les Dentellieres
-
Villejuif, Франция, 94805
- Institut Gustave Roussy
-
-
-
-
-
Busan, Южная Корея, 49241
- Pusan National University Hospital
-
Daejeon, Южная Корея, 35015
- Chungnam National University Hospital
-
Goyang-si, Южная Корея, 410-769
- National Cancer Center
-
Gwangju, Южная Корея, 61469
- Chonnam National University Hospital
-
Gyeonggi-do, Южная Корея, 13620
- Seoul National University Bundang Hospital
-
Incheon, Южная Корея, 21565
- Gachon University Gil Medical Center
-
Seoul, Южная Корея, 03080
- Seoul National University Hospital
-
Seoul, Южная Корея, 03722
- Severance Hospital Yonsei University Health System
-
Seoul, Южная Корея, 03181
- Kangbuk Samsung Hospital
-
Seoul, Южная Корея, 02841
- Korea University Anam Hospital
-
Seoul, Южная Корея, 135-710
- Samsung Medical Center
-
Wŏnju, Южная Корея, 26426
- Yonsei University Wonju Severance Christian Hospital
-
-
-
-
-
Chiba, Япония, 260-8717
- Chiba Cancer Center
-
Hirosaki, Япония, 036-8563
- Hirosaki University Hospital
-
Kashiwa, Япония, 277 8577
- National Cancer Center Hospital East
-
Kita Gun, Япония, 761 0793
- Kagawa University Hospital
-
Kobe, Япония, 650-0047
- Kobe City Medical Center General Hospital
-
Koshigaya, Япония, 343-8555
- Dokkyo Medical University Saitama Medical Center
-
Matsuyama, Япония, 791-0280
- Aso Co.,Ltd Iizuka Hospital
-
Miyazaki, Япония, 889-1692
- University of Miyazaki Hospital
-
Nagano, Япония, 381-8551
- Nagano Municipal Hospital
-
Nagoya, Япония, 464 8681
- Aichi Cancer Center Hospital
-
Osaka, Япония, 545 8586
- Osaka City University Hospital
-
Osaka, Япония, 541 8567
- Osaka International Cancer Institute
-
Sagamihara, Япония, 252-0375
- Kitasato University Hospital
-
Sakura, Япония, 285-8741
- Toho University Sakura Medical Center
-
Sapporo, Япония, 003-0804
- National Hospital Organization Hokkaido Cancer Center
-
Shinjuku-ku, Япония, 162-8666
- Tokyo Women's Medical University Hospital
-
Tokyo, Япония, 105-8470
- Toranomon Hospital
-
Tokyo, Япония, 135 8550
- The Cancer Institute Hospital of JFCR 1
-
Tsukuba, Япония, 305 8576
- University of Tsukuba Hospital
-
Ube, Япония, 755-8505
- Yamaguchi University Hospital
-
Yokohama, Япония, 232 0024
- Yokohama City University Medical Center
-
Ōsaka-sayama, Япония, 589-8511
- Kindai University Hospital
-
Ōta-ku, Япония, 373-8550
- Gunma Prefectural Cancer Center
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Histologic demonstration of transitional cell carcinoma of the urothelium. Minor components ( less than [<] 50 percent [%] overall) of variant histology such as glandular or squamous differentiation, or evolution to more aggressive phenotypes such as sarcomatoid or micropapillary change are acceptable
- Metastatic or surgically unresectable urothelial cancer
- Documented progression of disease, defined as any progression that requires a change in treatment, prior to randomization
- Cohort 1: Prior treatment with an anti-PD-(L) 1 agent as monotherapy or as combination therapy; no more than 2 prior lines of systemic treatment. Cohort 2: No prior treatment with an anti-PD-(L) 1 agent; only 1 line of prior systemic treatment. Subjects who received neoadjuvant or adjuvant chemotherapy and showed disease progression within 12 months of the last dose are considered to have received systemic therapy in the metastatic setting.
- A woman of childbearing potential who is sexually active must have a negative pregnancy test (beta human chorionic gonadotropin [beta hCG]) at Screening (urine or serum)
- Participants must meet appropriate molecular eligibility criteria
- Eastern Cooperative Oncology Group (ECOG) performance status Grade 0, 1, or 2
- Adequate bone marrow, liver, and renal function
Exclusion Criteria:
- Treatment with any other investigational agent or participation in another clinical study with therapeutic intent within 30 days prior to randomization
- Active malignancies (that is, requiring treatment change in the last 24 months). The only allowed exceptions are: urothelial cancer, skin cancer treated within the last 24 months that is considered completely cured, localized prostate cancer with a gleason score of 6 (treated within the last 24 months or untreated and under surveillance) and localized prostate cancer with a gleason score of 3+4 that has been treated more than 6 months prior to full study screening and considered to have a very low risk of recurrence.
- Symptomatic central nervous system metastases
- Received prior fibroblast growth factor receptor (FGFR) inhibitor treatment
- Known allergies, hypersensitivity, or intolerance to erdafitinib or its excipients
- Current central serous retinopathy (CSR) or retinal pigment epithelial detachment of any grade.
- History of uncontrolled cardiovascular disease
- Impaired wound healing capacity defined as skin/decubitus ulcers, chronic leg ulcers, known gastric ulcers, or unhealed incisions
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Cohort 1 (Arm 1A): Erdafitinib
Participants will be screened based on Fibroblast Growth Factor Receptor Inhibitor Clinical Trial Assay (FGFRi CTA) to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (treated with prior anti-programmed cell death protein PD-[L] 1 agent) will swallow erdafitinib tablets orally at a starting dose of 8 milligram (mg), once daily for 21 days in a 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustment are based on phosphate level and observed toxicity (adverse events [AEs]). Participants who enter in Long-term extension (LTE) phase will continue to receive the erdafitinib tablet as per investigator's decision. |
Participants will swallow erdafitinib tablets orally at a starting dose of 8 mg.
Другие имена:
FGFRi CTA will be used to determine molecular eligibility. |
|
Экспериментальный: Cohort 1 (Arm 1B): Vinflunine or Docetaxel
Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (treated with prior anti-PD-[L] 1 agent) will receive vinflunine 320 milligram per meter square (mg/m^2) as a 20-minute intravenous infusion once every 3 weeks or docetaxel 75 mg/m^2 as a 1 hour intravenous infusion every 3 weeks. Treatment with either agent (choice of investigator) will be administered until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on observed toxicities. Participants who enter in LTE phase will continue to receive Vinflunine or Docetaxel until the participant can commercially receive chemotherapy within the local healthcare system. |
FGFRi CTA will be used to determine molecular eligibility. Participants will receive vinflunine 320 mg/m^2 as a 20-minute intravenous infusion. Participants will receive docetaxel 75 mg/m^2 as a 1 hour intravenous infusion. |
|
Экспериментальный: Cohort 2 (Arm 2A): Erdafitinib
Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (no prior treatment with anti-PD-[L] 1 agent) will swallow erdafitinib tablets orally at a starting dose of 8 mg, once daily for 21 days in a 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on phosphate level and observed toxicity (AEs). Participants who enter in LTE phase will continue to receive the erdafitinib tablet as per investigator's decision. |
Participants will swallow erdafitinib tablets orally at a starting dose of 8 mg.
Другие имена:
FGFRi CTA will be used to determine molecular eligibility. |
|
Экспериментальный: Cohort 2 (Arm 2B): Pembrolizumab
Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (no prior treatment with anti-PD-[L] 1 agent) will receive pembrolizumab 200 mg as a 30-minute intravenous infusion once every 3 weeks, until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on observed toxicities. Participants who enter in LTE phase will continue to receive the pembrolizumab until 2 years after the first dose of pembrolizumab (at start of study) or until the participant can commercially receive pembrolizumab within the local healthcare system, whichever comes first. |
FGFRi CTA will be used to determine molecular eligibility. Participants will receive pembrolizumab 200 mg as a 30-minute intravenous infusion. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Overall Survival (OS)
Временное ограничение: From randomization (3 days prior to Cycle 1 Day 1) until death due to any cause (maximum up to 51.7 months)
|
Overall survival was measured from the date of randomization to the date of the participant's death. |
From randomization (3 days prior to Cycle 1 Day 1) until death due to any cause (maximum up to 51.7 months)
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Progression Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1
Временное ограничение: From randomization (3 days prior to Cycle 1 Day 1) until disease progression or relapse from CR or death (maximum up to 51.7 months)
|
PFS was defined as the time from the date of randomization to the date of disease progression or relapse from complete response (CR) based on investigator assessment using RECIST v 1.1, or death due to any cause, whichever occurred first. As per RECIST v 1.1, CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in the short axis to less than (<) 10 millimeters (mm). Progressive disease (PD) was defined as at least 20 percent (%) increase in the sum of diameters of measured lesions taking as references the smallest sum of diameters recorded on study (including baseline) and an absolute increase of greater than or equal to (>=) 5 mm or appearance of at least 1 new lesion. |
From randomization (3 days prior to Cycle 1 Day 1) until disease progression or relapse from CR or death (maximum up to 51.7 months)
|
|
Objective Response Rate (ORR) Per RECIST Version 1.1
Временное ограничение: From start of the treatment (Day 1 Cycle 1) up to maximum of 51.7 months
|
ORR was defined as the percentage of participants who achieved CR or partial response (PR) as determined by investigator per RECIST v1.1. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in the short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. |
From start of the treatment (Day 1 Cycle 1) up to maximum of 51.7 months
|
|
Change From Baseline in Physical Functioning Scales of the Functional Assessment of Cancer Therapy - Bladder Cancer (FACT-Bl)
Временное ограничение: Baseline up to Cycle 11 (each cycle was of 21 days)
|
The FACT-Bl consisted of 39 items, with 5-point Likert scales, covering 5 primary domains: physical well-being, social/family well-being, emotional well-being, functional well-being and additional concerns for participants with bladder cancer. The response options ranged from 0 to 4 where, 0='Not at all" and 4= "very much." FACT-Bl total score ranged from 0 (worst) to 156 (best). The higher the score, the better the quality of life (QOL). The baseline value was defined as the value collected at the time closest to but prior to the randomization. |
Baseline up to Cycle 11 (each cycle was of 21 days)
|
|
Time Until Symptom Deterioration
Временное ограничение: Randomization (3 days prior to Cycle 1 Day 1) up to maximum of 51.7 months
|
Time until symptom deterioration was defined as the first time to increase in urinary bladder cancer symptoms score from the day of randomization beyond a meaningful change threshold compared to baseline. The urinary bladder cancer symptom score was subset of FACT-Bl which included 3 items related to urinary symptoms, 5-point Likert scale. Response options ranged from 0 to 4, 0 = Not at all, 1= A little bit, 2= Somewhat, 3=Quite a bit, 4 = Very much. A response of 0 indicated no symptoms and 4 indicated severe symptoms. Total sum scores ranged from 0 to 12, higher scores indicate relatively poor quality of life. |
Randomization (3 days prior to Cycle 1 Day 1) up to maximum of 51.7 months
|
|
Percentage of Participants With Shift From Baseline in Patient-Global Impression of Severity (PGIS)
Временное ограничение: Baseline, 51.7 months
|
The PGI-S was a single item patient-reported measure assessing participants' impression of severity in bladder cancer symptoms. It uses a 4-point Likert scale as follows: symptoms are: 0-"absent (no symptoms)", 1-"mild", 2-"moderate", 3="severe" and 4= "very severe". Percentage of participants with shift from baseline in PGIS score were reported. A negative shift from baseline in PGIS score indicated Improvement and positive shift from baseline in PGIS score indicated Worsening. The baseline value was defined as the value collected at the time closest to but prior to the randomization. |
Baseline, 51.7 months
|
|
Change From Baseline in Utility Scale of the European Quality of Life-5 Dimensions-5 Levels Questionnaire (EQ-5D-5L)
Временное ограничение: Baseline up to Cycle 11 (each cycle was of 21 days)
|
The EQ-5D-5L was a generic measure of health status. The EQ-5D-5L was a 5-item questionnaire that assessed 5 domains included mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Health utility values generated from the EQ-5D generally range from 0 (a state as bad as being dead) to 1 (full health), with higher scores indicating better QoL. The EQ visual analog scale (VAS) recorded the patient's self-rated health on a VAS, ranged from 0 (worst imaginable health state) to 100 (best imaginable health state), with higher scores indicating better QoL. The baseline value was defined as the value collected at the time closest to but prior to the randomization. |
Baseline up to Cycle 11 (each cycle was of 21 days)
|
|
Change From Baseline in Visual Analog Scale (VAS) of the European Quality of Life-5 Dimensions-5 Levels Questionnaire (EQ-5D-5L)
Временное ограничение: Baseline up to Cycle 11 (each cycle was of 21 days)
|
The EQ-5D-5L was a generic measure of health status. The EQ-5D-5L was a 5-item questionnaire that assessed 5 domains included mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Health utility values generated from the EQ-5D generally range from 0 (a state as bad as being dead) to 1 (full health), with higher scores indicating better QoL. The EQ VAS recorded the patient's self-rated health on a VAS, ranged from 0 (worst imaginable health state) to 100 (best imaginable health state), with higher scores indicating better QoL. The baseline value was defined as the value collected at the time closest to but prior to the randomization. |
Baseline up to Cycle 11 (each cycle was of 21 days)
|
|
Duration of Response (DOR) as Per RECIST Version 1.1
Временное ограничение: From date of first documented response to date of first documented PD or death whichever occurred first (maximum up to 51.7 months)
|
DOR was defined as time from the date of initial documentation of an overall response (CR or PR) to the date of first documented evidence of progressive disease (PD) (or relapse for participants who experience CR) or death. As per RECIST Version 1.1: CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in the short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD was defined as at least 20% increase in the sum of diameters of measured lesions taking as references the smallest sum of diameters recorded on study (including baseline) and an absolute increase of >=5 mm or appearance of at least 1 new lesion. |
From date of first documented response to date of first documented PD or death whichever occurred first (maximum up to 51.7 months)
|
|
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Временное ограничение: From start of the treatment (Day 1 Cycle 1) up to 30 days after last dose of study drug or start of subsequent anticancer therapy (maximum up to 51.7 months)
|
An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs were the events between first dose of study drug and up to 30 days after last dose or before start of new anticancer therapy, whichever occurred first. All TEAEs including serious and non-serious events were reported in this outcome measure. |
From start of the treatment (Day 1 Cycle 1) up to 30 days after last dose of study drug or start of subsequent anticancer therapy (maximum up to 51.7 months)
|
|
Number of Participants With Shift From Baseline Grade Less Than or Equal to (<=) 2 to Grade Greater Than or Equal to (>=) 3 Post-Baseline in Laboratory Parameter: Hematology
Временное ограничение: From baseline up to 30 days after last dose or start of new anticancer therapy, whichever occurred first (maximum up to 51.7 months)
|
Hematology parameters included: hemoglobin, platelet count, white blood cell (WBC) count, and absolute neutrophil count (ANC). According to national cancer institute (NCI)-common terminology criteria for adverse events (CTCAE) version 4.03: Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, urgent intervention indicated, Grade 5= death related to AE and Grade 0= normal. In this outcome measure number of participants with shifts from baseline (BL) Grade <= 2 to Grade >=3 post-baseline in any of hematology parameters are reported. The baseline value for safety assessment was defined as the value collected at the time closest to, but prior to, the administration of the first dose of study drug. Only those categories in which at least one participant had data were reported in this outcome measure. |
From baseline up to 30 days after last dose or start of new anticancer therapy, whichever occurred first (maximum up to 51.7 months)
|
|
Number of Participants With Shift From Baseline Grade <= 2 to Grade >=3 Post-Baseline in Laboratory Parameter: Chemistry
Временное ограничение: From baseline up to 30 days after last dose or start of new anticancer therapy, whichever occurred first (maximum up to 51.7 months)
|
Chemistry parameters included: albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, chloride, creatinine, bicarbonate, corrected calcium, magnesium, potassium, sodium, serum phosphate, serum parathyroid hormone. According to NCI-CTCAE version 4.03: Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, urgent intervention indicated, Grade 5= death related to AE and Grade 0= normal. In this outcome measure number of participants with shifts from baseline (BL) Grade <= 2 to Grade >=3 post-baseline in any of chemistry parameters are reported. The baseline value for safety assessment was defined as the value collected at the time closest to, but prior to, the administration of the first dose of study drug. Only those categories in which at least one participant had data were reported in this outcome measure. |
From baseline up to 30 days after last dose or start of new anticancer therapy, whichever occurred first (maximum up to 51.7 months)
|
|
Number of Participants With Abnormalities in Electrocardiograms (ECG) Parameters
Временное ограничение: Day 1 of Cycle 2 and 4 (Each Cycle 21 days)
|
Number of participants with abnormalities in ECG parameters were reported. The ECG variables included heart rate, RR interval, PR interval, QRS interval, QT interval and QT corrected according to Fridericia's formula (QTcF). ECG abnormality criteria include: Heart rate: Low <50 beats per minute (bpm); High > 100 bpm, RR interval: Low < 600 milliseconds (ms); High > 1000 ms, QT interval: High > 500 ms, QTc interval: High > (450 ms for males, 470 ms for females); increase to >500 ms. |
Day 1 of Cycle 2 and 4 (Each Cycle 21 days)
|
|
Change From Baseline in Vital Signs: Weight
Временное ограничение: Baseline, 51.7 months
|
Changes from baseline in vital signs (weight) was reported. The baseline value for safety assessment was defined as the value collected at the time closest to, but prior to, the administration of the first dose of study drug. |
Baseline, 51.7 months
|
|
Number of Participants With Shift From Baseline to Worst Post-baseline Ophthalmologic Examination: Amsler Grid Test
Временное ограничение: From baseline up to maximum of 51.7 months
|
Number of participants with shift from baseline to worst post-baseline in Amsler grid test was reported. Baseline and post-baseline visit findings included normal, abnormal CS (clinically significant) and abnormal NCS (not clinically significant). Clinical significance was determined by investigator's assessment. The baseline value for safety assessment was defined as the value collected at the time closest to, but prior to, the administration of the first dose of study drug. Only categories in which at least one participant had data for worsening post-baseline measurement was reported. |
From baseline up to maximum of 51.7 months
|
|
Number of Participants With Shift From Baseline to Worst Post-baseline Ophthalmologic Examination: Visual Acuity
Временное ограничение: From baseline up to maximum of 51.7 months
|
Number of participants with shift from baseline to worst post-baseline in visual acuity (VA) was reported. Worst post-baseline was defined as the visual acuity value that resulted in the largest change from baseline value for either eye. Baseline value was considered for the eye that reported the worst-post baseline value. Baseline and post-baseline visit visual acuity findings included: <= 20/30, >20/30 to <= 20/40, >20/40 to <= 20/80, >20/80 to <= 20/120, >20/120 to <= 20/160, >20/160 to <= 20/200, >20/200. The baseline value for safety assessment was defined as the value collected at the time closest to, but prior to, the administration of the first dose of study drug. Only categories in which at least one participant had data for worsening in visual acuity from baseline value to worst post-baseline measurement was reported. |
From baseline up to maximum of 51.7 months
|
|
Number of Participants With Shift From Baseline to Worst Post-baseline Ophthalmologic Examination: Optical Coherence Tomography: Subretinal Fluid
Временное ограничение: From baseline up to maximum of 51.7 months
|
Number of participants with shift from baseline to worst post-baseline in optical coherence tomography for subretinal fluid was reported. At the baseline visit, findings may have been absent or present/visible. At all post-baseline visits, findings were compared to baseline and results may have been increased, decreased, stable or resolved. The baseline value for safety assessment was defined as the value collected at the time closest to, but prior to, the administration of the first dose of study drug. Only category (shift from absent at baseline to increased at post-baseline) in which at least one participant had data for worsening post-baseline measurement was reported. |
From baseline up to maximum of 51.7 months
|
|
Number of Participants With Shift From Baseline to Worst Post-baseline Ophthalmologic Examination: Optical Coherence Tomography: Retinal Pigment Epithelium (RPE) Elevation
Временное ограничение: From baseline up to maximum of 51.7 months
|
Number of participants with shift from baseline to worst post-baseline in optical coherence tomography for RPE elevation was reported. At the baseline visit, findings may have been absent or present/visible. At all post-baseline visits, findings were compared to baseline and results may have been increased, decreased, stable or resolved. The baseline value for safety assessment was defined as the value collected at the time closest to, but prior to, the administration of the first dose of study drug. Only categories in which at least one participant had data for worsening post-baseline measurement was reported. |
From baseline up to maximum of 51.7 months
|
|
Number of Participants With Shift From Baseline to Worst Post-baseline Ophthalmologic Examination: Slit Lamp Biomicroscopy: Retinal Assessment
Временное ограничение: From baseline up to maximum of 51.7 months
|
Number of participants with shift from baseline to worst post-baseline in slit lamp biomicroscopy examination for retinal assessment was reported. Baseline and post-baseline visit findings included normal, abnormal CS and abnormal NCS. Clinical significance was determined by investigator's assessment. The baseline value for safety assessment was defined as the value collected at the time closest to, but prior to, the administration of the first dose of study drug. Only categories in which at least one participant had data for worsening post-baseline measurement was reported. |
From baseline up to maximum of 51.7 months
|
|
Oral Clearance (CL/F) of Erdafitinib
Временное ограничение: Day 14 of Cycle 1, Day 1 of Cycle 2: pre-dose and 2-4 hours post-dose (each cycle was of 21 days)
|
Clearance was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes. |
Day 14 of Cycle 1, Day 1 of Cycle 2: pre-dose and 2-4 hours post-dose (each cycle was of 21 days)
|
|
Area Under the Plasma Concentration-Time Curve From Time Zero to Time 't' (AUC[0-t]) of Erdafitinib
Временное ограничение: Day 14 of Cycle 1, Day 1 of Cycle 2: pre-dose and 2-4 hours post-dose (each cycle is of 21 days)
|
Area under the plasma concentration time-curve from time zero to the time t (AUC[0-t]) was reported. |
Day 14 of Cycle 1, Day 1 of Cycle 2: pre-dose and 2-4 hours post-dose (each cycle is of 21 days)
|
Соавторы и исследователи
Следователи
- Директор по исследованиям: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Публикации и полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- CR108401
- 2017-002932-18 (Номер EudraCT)
- 42756493BLC3001 (Другой идентификатор: Janssen Research & Development, LLC)
- 2017 (Грант/контракт NIH США)
- 2023-510296-56-00 (Идентификатор реестра: EUCT number)
- 2023 (Грант/контракт NIH США)
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .